[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:biliary-cancer":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":26,"states":27},"Biliary Cancer",3,[7,14,20],{"nct_id":8,"title":9,"phases":10,"status":11,"updated_at":12,"content_modified":13},"NCT06101277","Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)",[],"RECRUITING","2026-08-26T02:16:24.970704Z","2026-07-05T05:32:16.744017Z",{"nct_id":15,"title":16,"phases":17,"status":11,"updated_at":18,"content_modified":19},"NCT05517811","Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection",[],"2026-08-26T02:15:00.557154Z","2026-05-13T02:55:06.353529Z",{"nct_id":21,"title":22,"phases":23,"status":11,"updated_at":24,"content_modified":25},"NCT01416714","Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy",[],"2026-08-26T02:18:02.701182Z","2026-05-13T02:55:06.072507Z",[],[]]